One of the main advantages of covalent inhibitors is their ability to achieve prolonged inhibition with lower doses, reducing the frequency of administration and potentially minimizing side effects. Additionally, the irreversible binding can overcome the issue of high turnover rates of the target protein, a common challenge in cancer therapy. This sustained action can be particularly beneficial in overcoming resistance mechanisms that cancer cells might develop against reversible inhibitors.
